OKYO Pharma’s (OKYO) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of OKYO Pharma (NASDAQ:OKYO) in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a $7.00 price objective on the stock. HC Wainwright also issued estimates for OKYO Pharma’s Q2 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.40) EPS.

OKYO Pharma Price Performance

NASDAQ OKYO opened at $1.26 on Thursday. OKYO Pharma has a twelve month low of $0.81 and a twelve month high of $2.12. The company’s 50-day simple moving average is $1.05 and its 200 day simple moving average is $1.24.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.